Alvelestat - AstraZeneca/Mereo BioPharma

Drug Profile

Alvelestat - AstraZeneca/Mereo BioPharma

Alternative Names: AZD-9668; MPH-966

Latest Information Update: 16 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer Allegheny Singer Research Institute; AstraZeneca; Mereo BioPharma; National Cancer Institute (USA)
  • Class Amides; Anti-inflammatories; Antibronchitics; Antihyperglycaemics; Pyrazoles; Pyridines
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alpha 1-antitrypsin deficiency; Type 2 diabetes mellitus
  • Phase I/II Bronchiolitis obliterans
  • Discontinued Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 25 Sep 2018 Mereo BioPharma plans the phase II ATALANTa trial for Alpha 1-antitrypsin deficiency in USA (PO, Tablet) (NCT03679598)
  • 08 Aug 2018 Phase-II clinical trials in Alpha 1-antitrypsin deficiency in European Union, USA (PO)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top